Clinical trial

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

Name
OHSU IRB 24952
Description
The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Trial arms
Trial start
2023-01-09
Estimated PCD
2026-12-31
Trial end
2027-12-31
Status
Recruiting
Phase
Early phase I
Treatment
Ulipristal acetate
Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
Arms:
Active CYP3A5 Allele, Inactive CYP3A5 Allele
Size
140
Primary endpoint
Delay in follicular rupture
over 1 menstrual cycle (assessed up to approximately 30 days)
Concentration of UPA
5 days after taking study drug
Eligibility criteria
Inclusion Criteria: * Generally healthy women * Aged 18-40 * regular menses (every 21-35 days) experiencing ovulatory cycles proven by a single progesterone level of 3 ng/mL or greater during the luteal phase of the screening cycle. Exclusion Criteria: * Pregnant, seeking pregnancy, or breastfeeding * Known allergy to study medication * Recent use of hormonal contraception * Irregular periods (\<21 days or \>35 day cycles) * Routine use of nonsteroidal anti-inflammatory drugs * Metabolic disorders * Smoking * Any condition that would preclude the provision of informed consent * Using drugs (within 2 weeks of study enrollment) known to interfere with the metabolism of UPA as well as drugs known to be CYP3A4 inducers, inhibitors, or CYP3A drug substrates
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 140, 'type': 'ESTIMATED'}}
Updated at
2023-04-11

1 organization

1 product

1 indication

Indication
Contraception